New test aims to predict who wins the fight against lymphoma with CAR-T
NCT ID NCT07472972
Summary
This study is testing a new, detailed tool called the INTeRCePT assay to see if it can predict which patients with a type of blood cancer (lymphoma) will respond well to a treatment called CAR-T cell therapy. The study will enroll 50 adults with lymphoma who are already scheduled to receive CAR-T therapy. The main goal is to see if this complex prediction tool can be successfully completed for each patient, which could help doctors make more personalized treatment decisions in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universityhospital Zurich, Department of Medical Oncology and Hematology
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.